[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beta Bionics Inc (BBNX)

Beta Bionics Inc (BBNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 526,723
  • Shares Outstanding, K 44,562
  • Annual Sales, $ 100,250 K
  • Annual Income, $ -73,200 K
  • EBIT $ -77 M
  • EBITDA $ -74 M
  • 60-Month Beta 3.29
  • Price/Sales 4.72
  • Price/Cash Flow N/A
  • Price/Book 1.74

Options Overview Details

View History
  • Implied Volatility 90.58% (-87.45%)
  • Historical Volatility 94.64%
  • IV Percentile 15%
  • IV Rank 6.90%
  • IV High 434.18% on 03/12/26
  • IV Low 65.12% on 12/26/25
  • Expected Move (DTE 25) 0.21 (1.80%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 160
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 2,680
  • Open Int (30-Day) 1,461
  • Expected Range 11.61 to 12.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.62
  • Number of Estimates 4
  • High Estimate $-0.57
  • Low Estimate $-0.66
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) -58.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.01 +31.19%
on 05/15/26
12.42 -4.83%
on 05/22/26
-0.38 (-3.11%)
since 04/22/26
3-Month
8.80 +34.32%
on 04/10/26
14.13 -16.35%
on 02/24/26
-1.88 (-13.72%)
since 02/20/26
52-Week
8.80 +34.32%
on 04/10/26
32.71 -63.86%
on 11/26/25
-3.69 (-23.79%)
since 05/22/25

Most Recent Stories

More News
Beta Bionics Updates Commercialization Timeline Expectations for Mintâ„¢, its Patch Pump in Development

IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to...

BBNX : 11.82 (+11.40%)
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans

Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales...

BBNX : 11.82 (+11.40%)
Beta Bionics to Present at the Bank of America Securities Health Care Conference

IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management...

BBNX : 11.82 (+11.40%)
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results...

BBNX : 11.82 (+11.40%)
Beta Bionics: The FDA Remediation Deadline Arrives as Growth Momentum Gets Its First Real Test

Barchart Research What to Expect from BBNX Earnings BBNX Generated April 20, 2026 Current Price $12.91 EPS Estimate $$-0.53 Consensus Rating Moderate Buy Average Move 13.49% Beta Bionics: The FDA Remediation...

BBNX : 11.82 (+11.40%)
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of  Bionic Insights™ , an innovative new feature within its Bionic Reports, designed to help healthcare providers...

BBNX : 11.82 (+11.40%)
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026

IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...

BBNX : 11.82 (+11.40%)
BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their...

BBNX : 11.82 (+11.40%)
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Bionics (NASDAQ: BBNX)

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 11.82 (+11.40%)
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 11.82 (+11.40%)

Business Summary

Beta Bionics Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of solutions. Beta Bionics Inc. is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 13.90
2nd Resistance Point 13.16
1st Resistance Point 12.49
Last Price 11.82
1st Support Level 11.08
2nd Support Level 10.34
3rd Support Level 9.67

See More

52-Week High 32.71
Fibonacci 61.8% 23.58
Fibonacci 50% 20.75
Fibonacci 38.2% 17.93
Last Price 11.82
52-Week Low 8.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.